Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06993844 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors and Advanced Breast Cancer, sponsored by Ensem Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 233
- Enrollment target
- 10
- Study locations
NCT06993844 is a Phase 1 study of Advanced Solid Tumors and Advanced Breast Cancer that is actively recruiting participants, run by Ensem Therapeutics. The registered enrollment target is 233 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (18% higher). The trial reports 10 study locations across 7 states.
The verdict
NCT06993844, a Phase 1 study of Advanced Solid Tumors and Advanced Breast Cancer, is actively recruiting participants, sponsored by Ensem Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 233 participants
- Enrollment target
- 10
- Study locations
Study Summary
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
Conditions Studied
Interventions
- DRUG ETX-636 dose escalation
- DRUG ETX-636 dose escalation in combination with fulvestrant
- DRUG ETX-636 dose expansion in combination with fulvestrant
Study Locations (10)
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- START - San Antonio
Connecticut
- Yale University, Yale Cancer Center - New Haven
North Carolina
- Carolina BioOncology Institute - Huntersville
Virginia
- NEXT - Fairfax
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06993844
The ClinicalTrials.gov registry entry for NCT06993844 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (18% higher). The listed sponsor is Ensem Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which ETX-636 dose escalation is the first listed.
NCT06993844 reports 10 study locations spanning 7 distinct geographic areas - top geographies include California, Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT06993844 about?
NCT06993844 is a clinical study titled "Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors". Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
What is the current status of trial NCT06993844?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 233 participants. The study started on 2025-06-10. Estimated completion is 2027-12-30.
What conditions does trial NCT06993844 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Advanced Breast Cancer.
What interventions are being tested in trial NCT06993844?
The interventions under investigation include: ETX-636 dose escalation (DRUG), ETX-636 dose escalation in combination with fulvestrant (DRUG), ETX-636 dose expansion in combination with fulvestrant (DRUG).
Who is sponsoring clinical trial NCT06993844?
This trial is sponsored by Ensem Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06993844 being conducted?
This trial has 10 study locations across California, Connecticut, Massachusetts, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.